Sector
HealthcareOpen
₹10.2Prev. Close
₹9.72Turnover(Lac.)
₹2.86Day's High
₹10.2Day's Low
₹9.552 Week's High
₹12.4652 Week's Low
₹3.62Book Value
₹-0.9Face Value
₹10Mkt Cap (₹ Cr.)
72.74P/E
0EPS
0Divi. Yield
014 Nov 2023
12:00 AM
BookCloser
12 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
14 Nov 2023
12:00 AM
AGM
Announcement Date: 14 Nov, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -81.98 | -75.97 | -71.11 | -60.67 |
Net Worth | -6.21 | -0.2 | 4.66 | 15.1 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0.16 | 0 | 0.11 | 0.28 |
yoy growth (%) | 4,642.12 | -96.97 | -57.89 | 54.7 |
Raw materials | -0.06 | -0.01 | -0.04 | 0 |
As % of sales | 35.87 | 413.59 | 41.19 | 0 |
Employee costs | -0.24 | -0.28 | -0.32 | -0.55 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -10.43 | -10.96 | -5.65 | -19.86 |
Depreciation | -9.9 | -9.89 | -9.89 | -17.52 |
Tax paid | 0 | 0 | -0.78 | 0 |
Working capital | 0.23 | 0.05 | -6.9 | -1.21 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 4,642.12 | -96.97 | -57.89 | 54.7 |
Op profit growth | -39.12 | -58.98 | -17.78 | 126.39 |
EBIT growth | -3.92 | 128.82 | -76.2 | -9.47 |
Net profit growth | -4.82 | 70.26 | -67.58 | -7.78 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 0.23 | 0.06 | 0.09 | 0.17 | 0 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 0.23 | 0.06 | 0.09 | 0.17 | 0 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.18 | 0.18 | 0.21 | 0.27 | 0.18 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Apollo Hospitals Enterprise Ltd APOLLOHOSP | 6,385 | 90.85 | 91,806.5 | 238.8 | 0.09 | 1,894.6 | 536.28 |
Max Healthcare Institute Ltd MAXHEALTH | 920.05 | 130.13 | 89,420.8 | 241.77 | 0.16 | 610.11 | 79.02 |
Fortis Healthcare Ltd FORTIS | 480.8 | 293.17 | 36,298.39 | 68.33 | 0.21 | 307.48 | 120.36 |
Global Health Ltd MEDANTA | 1,202.5 | 89.61 | 32,288.01 | 92.24 | 0 | 578.65 | 106.09 |
Narayana Hrudayalaya Ltd NH | 1,242 | 59.8 | 25,381.61 | 158.09 | 0.32 | 846.31 | 90.04 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
Sujana Kadiam
Company Sec. & Compli. Officer
Ankita Jain
Independent Director
Santosh Kumar
Chairman & Managing Director
K Koteswara Rao
Independent Director
Marri Swetha
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Transgene Biotek Ltd
Summary
Founded in March, 1990 by Dr. Koteswara Rao, Transgene Biotek Ltd was one of the first Biotechnology companies in India. Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc. The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune.Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.Transgene Bioteks products are exported to Africa, Russia, China, Malaysia and the Phillipines. The company chalked out a new project for setting up a manufacturing facility costing Rs. 30 crore at the Anrich Industrial Area, Bollaram. TBL is working of four new plants comprising of Oral deliver of proteins and peptides; DNA vaccines; fusion proteins and bio therapeutics. The new project is funded through preferential offer to Batterymarch Financial Management USA and Other Financial Institutions (FIs).The Company absorbed the transfer of technology from RBB Inc, USA for the manufacture and marketing of Erythropoietin during year 2003. The Scheme of Arrangement for Amalgamation of M/S Saket Bi
Read More
What is the Transgene Biotek Ltd share price today?
The Transgene Biotek Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹9.6 today.
What is the Market Cap of Transgene Biotek Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Transgene Biotek Ltd is ₹72.74 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Transgene Biotek Ltd?
The PE and PB ratios of Transgene Biotek Ltd is 0 and -10.72 as of 22 Jul ‘24
What is the 52 Week High and Low of Transgene Biotek Ltd?
The 52-week high/low is the highest and lowest price at which a Transgene Biotek Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Transgene Biotek Ltd is ₹3.62 and ₹12.46 as of 22 Jul ‘24
What is the CAGR of Transgene Biotek Ltd?
Transgene Biotek Ltd's CAGR for 5 Years at 27.72%, 3 Years at 31.24%, 1 Year at 150.52%, 6 Month at -14.06%, 3 Month at 33.33% and 1 Month at 9.95%.
What is the shareholding pattern of Transgene Biotek Ltd?
The shareholding pattern of Transgene Biotek Ltd is as follows:
Promoters - 21.68 %
Institutions - 0.00 %
Public - 70.04 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
